JP3038339B2
(ja)
*
|
1988-05-02 |
2000-05-08 |
ザイナクシス・テクノロジーズ・インコーポレーテッド |
バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
|
US6252060B1
(en)
|
1988-07-07 |
2001-06-26 |
Nexstar Pharmaceuticals, Inc. |
Antiviral liponucleosides: treatment of hepatitis B
|
US5817638A
(en)
*
|
1988-07-07 |
1998-10-06 |
Nexstar Pharmaceuticals, Inc. |
Antiviral liponucleosides: treatment of hepatitis B
|
US6599887B2
(en)
|
1988-07-07 |
2003-07-29 |
Chimerix, Inc. |
Methods of treating viral infections using antiviral liponucleotides
|
US5411947A
(en)
*
|
1989-06-28 |
1995-05-02 |
Vestar, Inc. |
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
US5194654A
(en)
*
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5463092A
(en)
*
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
US5563257A
(en)
*
|
1990-08-20 |
1996-10-08 |
Boehringer Mannheim Gmbh |
Phospholipid derivatives of nucleosides
|
DE4026265A1
(de)
*
|
1990-08-20 |
1992-02-27 |
Boehringer Mannheim Gmbh |
Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
US20020120130A1
(en)
*
|
1993-09-10 |
2002-08-29 |
Gilles Gosselin |
2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
|
FR2714382B1
(fr)
*
|
1993-12-27 |
1996-02-02 |
Roussel Uclaf |
Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
|
US5627216A
(en)
*
|
1994-02-07 |
1997-05-06 |
Papadopoulos; George D. |
Medicinal ointment for hemorrhoid and skin care
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
US5696277A
(en)
*
|
1994-11-15 |
1997-12-09 |
Karl Y. Hostetler |
Antiviral prodrugs
|
AU706267B2
(en)
*
|
1994-11-30 |
1999-06-10 |
Supergen, Inc. |
Phosphocholine drug derivatives
|
ZA96525B
(en)
*
|
1995-02-06 |
1996-08-06 |
Astra Ab |
Novel pharmaceutical compositions
|
DE69638099D1
(de)
|
1995-05-04 |
2010-01-28 |
Gilead Sciences Inc |
Nukleinsäureligand-komplexe
|
WO1996039148A1
(en)
*
|
1995-06-06 |
1996-12-12 |
University Of Southern California |
Methods and compositions for inhibiting cytomegalovirus replication
|
US7517858B1
(en)
*
|
1995-06-07 |
2009-04-14 |
The Regents Of The University Of California |
Prodrugs of pharmaceuticals with improved bioavailability
|
PT831852E
(pt)
|
1995-06-07 |
2007-02-28 |
Uab Research Foundation |
Nucleósidos com actividade anti-vírus da hepatite b
|
TW343975B
(en)
*
|
1995-12-15 |
1998-11-01 |
Boehringer Mannheim Gmbh |
New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
|
DE19547022A1
(de)
*
|
1995-12-15 |
1997-06-19 |
Boehringer Mannheim Gmbh |
Kovalente Lipid-Phosphonocarbonsäure-Konjugate, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
|
AU2230497A
(en)
*
|
1996-02-26 |
1997-09-10 |
Daiichi Pharmaceutical Co., Ltd. |
Liposome and liposome dispersion
|
US5734040A
(en)
*
|
1996-03-21 |
1998-03-31 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
US6274313B1
(en)
|
1996-03-21 |
2001-08-14 |
Pioneer-Hybrid International, Inc. |
Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use
|
US6331617B1
(en)
|
1996-03-21 |
2001-12-18 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5919815A
(en)
*
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
WO1997044026A1
(en)
*
|
1996-05-22 |
1997-11-27 |
Neuromedica, Inc. |
Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
|
US5869446A
(en)
*
|
1996-07-09 |
1999-02-09 |
Gambit International Limited |
Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections
|
US6440980B1
(en)
*
|
1996-09-17 |
2002-08-27 |
Avanir Pharmaceuticals |
Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
|
JP2002514183A
(ja)
*
|
1996-09-17 |
2002-05-14 |
スーパージェン・インコーポレーテッド |
リン脂質薬剤誘導体
|
SE9603726D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
Novel compounds
|
US6686462B2
(en)
*
|
1997-02-28 |
2004-02-03 |
The Regents Of The University Of California |
Antiviral compounds and methods of administration
|
EA005097B1
(ru)
*
|
1997-03-19 |
2004-10-28 |
Эмори Юниверсити |
Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
|
US5830432A
(en)
*
|
1997-03-31 |
1998-11-03 |
Amur Pharmacuticals, Inc. |
Phospholipid drug derivatives
|
US5869469A
(en)
*
|
1997-08-18 |
1999-02-09 |
Queen's University At Kingston |
Phosphonocarboxylate compounds for treating amyloidosis
|
EP1058686B1
(de)
|
1998-02-25 |
2006-11-02 |
Emory University |
2'-fluoronukleoside
|
US6329356B1
(en)
|
1998-04-10 |
2001-12-11 |
Neurochem, Inc. |
Phosphono-carboxylate compounds for treating amyloidosis
|
US6310073B1
(en)
|
1998-07-28 |
2001-10-30 |
Queen's University At Kingston |
Methods and compositions to treat glycosaminoglycan-associated molecular interactions
|
US6444652B1
(en)
*
|
1998-08-10 |
2002-09-03 |
Novirio Pharmaceuticals Limited |
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
|
WO2000009531A2
(en)
|
1998-08-10 |
2000-02-24 |
Novirio Pharmaceuticals Limited |
β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
|
EP1431304B1
(de)
|
1998-08-10 |
2014-12-03 |
Novartis AG |
Beta-L-2'-Deoxy-Nukleoside für die Behandlung von Hepatitis B
|
DK1382343T3
(da)
|
1998-11-02 |
2010-04-26 |
Gilead Sciences Inc |
Kombinationsterapi til behandling af hepatitis B-virus
|
EP1144420B1
(de)
*
|
1999-01-15 |
2003-12-10 |
Board Of Trustees Of The University Of Illinois |
Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
AU4282400A
(en)
*
|
1999-04-28 |
2000-11-10 |
Neurochem (International) Limited |
Compositions and methods for treating amyloidosis
|
US6562836B1
(en)
|
1999-05-24 |
2003-05-13 |
Queen's University Of Kingston |
Methods and compounds for inhibiting amyloid deposits
|
BR0016652A
(pt)
|
1999-12-23 |
2002-11-19 |
Neurochem Inc |
Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
|
MXPA02006491A
(es)
*
|
1999-12-29 |
2002-11-29 |
Univ California |
Tratamiento de infeccion por el virus de la inmunodeficiencia humana resistente a farmacos.
|
US6670342B2
(en)
|
2000-03-29 |
2003-12-30 |
Georgetown University |
Method of treating hepatitis delta virus infection
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
EP1294735A2
(de)
*
|
2000-05-26 |
2003-03-26 |
Novirio Pharmaceuticals Limited |
Verfahren und zusammensetzungen zur behandlung von flaviviren und pestiviren
|
US6875751B2
(en)
*
|
2000-06-15 |
2005-04-05 |
Idenix Pharmaceuticals, Inc. |
3′-prodrugs of 2′-deoxy-β-L-nucleosides
|
KR101201552B1
(ko)
|
2000-10-18 |
2012-11-15 |
파마셋 인코포레이티드 |
바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
|
EP1903041B1
(de)
|
2001-03-01 |
2015-02-18 |
AbbVie Inc. |
Polymorphe und andere kristalline Formen von Cis-FTC
|
ATE556706T1
(de)
*
|
2001-03-23 |
2012-05-15 |
Luitpold Pharm Inc |
Fettalkohol-arzneimittel-konjugate
|
EP1427407A4
(de)
*
|
2001-03-23 |
2005-05-11 |
Luitpold Pharm Inc |
Fettamin-arzneimittel-konjugate
|
US20060029655A1
(en)
*
|
2001-06-25 |
2006-02-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Method for preparation of vesicles loaded with biological material and different uses thereof
|
EP1435974A4
(de)
*
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
Verfahren und zusamemnsetzungen zur behandlung des hepatitis-c-virus mit 4'-modifizierten nucleosiden
|
WO2003032915A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Avanir Pharmacueticals |
Viral inhibition by n-docosanol
|
SE521676C2
(sv)
*
|
2002-01-02 |
2003-11-25 |
Dilafor Ab |
Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
RS114004A
(en)
|
2002-06-28 |
2007-02-05 |
Idenix (Cayman) Limited, |
Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
|
KR20050035194A
(ko)
*
|
2002-06-28 |
2005-04-15 |
이데닉스 (케이만) 리미티드 |
플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
|
TWI244393B
(en)
*
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
AU2003278816A1
(en)
*
|
2002-09-13 |
2004-04-30 |
Idenix (Cayman) Limited |
ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
|
CN1849142A
(zh)
*
|
2002-11-15 |
2006-10-18 |
埃迪尼克斯(开曼)有限公司 |
2′-支链核苷和黄病毒突变
|
US7598373B2
(en)
*
|
2002-12-12 |
2009-10-06 |
Idenix Pharmaceuticals, Inc. |
Process for the production of 2-C-methyl-D-ribonolactone
|
AU2003300434A1
(en)
*
|
2002-12-23 |
2004-07-22 |
Idenix (Cayman) Limited |
Process for the production of 3'-nucleoside prodrugs
|
US20040171175A1
(en)
*
|
2003-02-28 |
2004-09-02 |
Swanson Basil I. |
Process for conjugating biomolecules to hydrophobic membrane-incorporated molecules
|
EP2345661A1
(de)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modifizierte fluorinierte Nukleosidanaloga
|
US20070010573A1
(en)
*
|
2003-06-23 |
2007-01-11 |
Xianqi Kong |
Methods and compositions for treating amyloid-related diseases
|
US7414076B2
(en)
|
2003-06-23 |
2008-08-19 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
US7244764B2
(en)
*
|
2003-06-23 |
2007-07-17 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
DK1658302T3
(da)
|
2003-07-25 |
2010-11-22 |
Idenix Pharmaceuticals Inc |
Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
|
WO2005094322A2
(en)
|
2004-03-29 |
2005-10-13 |
University Of South Florida |
Effective treatment of tumors and cancer with triciribine and related compounds
|
EP1912643A2
(de)
*
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
5-aza-7-deazapurinderivate zur behandlung von infektionen mit flaviviridae
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
AU2005285045B2
(en)
*
|
2004-09-14 |
2011-10-13 |
Gilead Pharmasset Llc |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
BRPI0517790A
(pt)
*
|
2004-11-12 |
2008-10-21 |
Neurochem Int Ltd |
métodos e composições fluoradas para tratar doenças relacionadas à amilóide
|
EP1817305A2
(de)
*
|
2004-11-16 |
2007-08-15 |
Neurochem (International) Limited |
Verbindungen zur behandlung von cns- und amyloidassoziierten krankheiten
|
EP1836161B1
(de)
|
2004-12-22 |
2016-07-20 |
BHI Limited Partnership |
Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
|
EP1868628B1
(de)
*
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Verbindungen, zusammensetzungen und verfahren zur behandlung von pockenvirus-infektionen
|
EP2842559A3
(de)
|
2005-04-08 |
2015-03-18 |
Chimerix, Inc. |
Verbindungen, Zusammensetzungen und Verfahren zur Behandlung viraler Infektionen und anderer Erkrankungen
|
EA200800932A1
(ru)
*
|
2005-09-26 |
2008-10-30 |
Фармассет, Инк. |
Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
|
EP1976382B1
(de)
*
|
2005-12-23 |
2013-04-24 |
IDENIX Pharmaceuticals, Inc. |
Verfahren zur herstellung eines synthetischen zwischenprodukts für die herstellung von verzweigten nukleosiden
|
US8895531B2
(en)
*
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
PT3851447T
(pt)
|
2006-10-12 |
2023-12-11 |
Bellus Health Inc |
Métodos, compostos, composições e veículos para administrar ácido 3-amino-1-propanossulfónico
|
GB0700133D0
(en)
|
2007-01-04 |
2007-02-14 |
Humabs Llc |
Human cytomegalovirus neutralising antibodies and use thereof
|
US7947274B2
(en)
*
|
2007-01-04 |
2011-05-24 |
Humabs, LLC. |
Human cytomegalovirus neutralising antibodies and use thereof
|
US7964580B2
(en)
*
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2009094190A2
(en)
*
|
2008-01-25 |
2009-07-30 |
Chimerix, Inc. |
Methods of treating viral infections
|
MX2010010619A
(es)
|
2008-03-28 |
2010-12-17 |
Altiris Therapeutics |
Moduladores de quimioquina.
|
CA2722308C
(en)
|
2008-04-15 |
2024-02-27 |
Rfs Pharma, Llc. |
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
PE20141433A1
(es)
|
2008-07-16 |
2014-10-19 |
Inst Research In Biomedicine |
Anticuerpos neutralizantes de citomegalovirus humano
|
AU2009329872B2
(en)
|
2008-12-23 |
2016-07-07 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
SG172361A1
(en)
*
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside analogs
|
AR074897A1
(es)
*
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
PL3338765T3
(pl)
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
EP3216789A1
(de)
|
2010-02-12 |
2017-09-13 |
Chimerix, Inc. |
Verfahren zur behandlung von vireninfektionen
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
EP2752422B1
(de)
|
2010-03-31 |
2017-08-16 |
Gilead Pharmasset LLC |
Stereoselektive synthese von phosphorhaltigen wirkstoffen
|
AU2011248620B2
(en)
|
2010-04-26 |
2015-11-26 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
CN103748078B
(zh)
|
2011-06-08 |
2016-11-09 |
夏尔人类遗传性治疗公司 |
可裂解脂质
|
EP4043025A1
(de)
|
2011-06-08 |
2022-08-17 |
Translate Bio, Inc. |
Lipidnanoteilchenzusammensetzungen und verfahren zur mrna-freisetzung
|
MD4589C1
(ro)
|
2011-09-16 |
2019-03-31 |
Gilead Pharmasset Llc |
Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
CN104487055A
(zh)
|
2012-03-29 |
2015-04-01 |
夏尔人类遗传性治疗公司 |
脂质衍生的中性纳米颗粒
|
CN104334161A
(zh)
|
2012-03-29 |
2015-02-04 |
夏尔人类遗传性治疗公司 |
可电离的阳离子脂质
|
EP2859102A4
(de)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
Nukleaseresistente polynukleotide und verwendungen davon
|
NZ625087A
(en)
|
2013-01-31 |
2017-05-26 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
PT2968586T
(pt)
|
2013-03-14 |
2018-11-13 |
Ethris Gmbh |
Composições de arnm de cftr e métodos e utilizações relacionados
|
EP2970955B1
(de)
|
2013-03-14 |
2018-11-14 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
EP3388834B1
(de)
|
2013-03-15 |
2020-04-15 |
Translate Bio, Inc. |
Synergistische verbesserung der abgabe von nukleinsäuren durch gemischte formulierungen
|
ES2900570T3
(es)
|
2013-08-27 |
2022-03-17 |
Gilead Pharmasset Llc |
Formulación de combinación de dos compuestos antivirales
|
WO2015061491A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
AU2014340092B2
(en)
|
2013-10-22 |
2019-09-19 |
Translate Bio, Inc. |
mRNA therapy for Argininosuccinate Synthetase Deficiency
|
SG11201608725YA
(en)
|
2014-04-25 |
2016-11-29 |
Shire Human Genetic Therapies |
Methods for purification of messenger rna
|
WO2018157154A2
(en)
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Novel codon-optimized cftr mrna
|
EP3624824A1
(de)
|
2017-05-16 |
2020-03-25 |
Translate Bio, Inc. |
Behandlung von zystischer fibrose durch verabreichung von codonoptimierter mrna, die cftr codiert
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
JP7275111B2
(ja)
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の生成方法
|
AU2019325702A1
(en)
|
2018-08-24 |
2021-02-25 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|